Comparative neoadjuvant therapy in triple-negative breast cancer
Which neoadjuvant treatments for triple-negative breast cancer have the strongest comparative evidence for efficacy and safety?
Following this dossier helps readers see whether evidence syntheses are clarifying the relative benefits and risks of treatment options over time. It also shows when conclusions rest on updated comparisons rather than a single review.
Where it stands now
Main bottleneck
Current evidence shows successive systematic reviews and network meta-analyses, but does not establish which options have reliably superior outcomes or safety. Comparative conclusions remain unresolved in the supplied evidence.
Watch next
Watch for a published comparative review or network meta-analysis that reports updated efficacy and safety comparisons among first-line neoadjuvant treatments.
Progress timeline
How the evidence has changed over time.
2023 · 1 update
- Why did immune treatment plus platinum stand out before surgery for triple-negative breast cancer?Source date 2023-09-01
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: Why better tumor response did not settle the treatment trade-off in triple-negative breast cancer
Previous expectation: Future evidence might identify which patients and chemotherapy backbones benefit most from immune-plus-platinum treatment while limiting harm.
What this study adds: This synthesis compares 26 studies involving 9,714 patients and highlights the combination’s pathological complete response and safety profile among treatment options. Its searches covered reports published before March 31, 2022.
Current research note
2022 · 1 update
- Why better tumor response did not settle the treatment trade-off in triple-negative breast cancerPartly supportedSource date 2022-08-20
Since the previous research note · Partly supported
Track continuity
Since the previous research note: Did adding immune therapy improve response at surgery in both PD-L1 groups with triple-negative breast cancer?
Previous expectation: Presurgery immune treatment might reduce later disease events if the effect endured and added toxicity could be managed.
What this study adds: This 2022 synthesis associated the immune-plus-platinum combination with better disease-free or event-free survival than its chemotherapy reference, while also finding more premature treatment discontinuation. It did not establish an overall-survival gain or resolve treatment tolerability.
Current research note
2021 · 1 update
How this Track works
This page changes as new evidence arrives. Open any update to see what researchers found at that point in the story.